A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

Status:
Active, not recruiting

Trial end date:
2024-10-25

Target enrollment:

Participant gender:

A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.

Phase 1

Novartis Pharmaceuticals